Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9770120 | 0.82 | HDAC9 (0.41) | HDAC9ALDH1A1KMT2ACXCR5AKT1 | |
| SCHEMBL9770009 | 0.82 | HDAC9 (0.37) | NOTUMHDAC9ALDH1A1CXCR5CNR2 | |
| Hydrochloric Acid SCHEMBL9770018 | 0.81 | HDAC9 (0.40) | HDAC9ALDH1A1KMT2ACXCR5AKT1 | |
| SCHEMBL856404 | 0.77 | PTPN1 (0.33) | HDAC9ALDH1A1KMT2ACXCR5CNR1 | |
| SCHEMBL30681192 | 0.77 | PTPN1 (0.33) | HDAC9ALDH1A1KMT2ACXCR5CNR1 | |
| SCHEMBL9770038 | 0.76 | BRD4 (0.48) | ALDH1A1MEN1KMT2A | |
| SCHEMBL25699874 | 0.74 | MEN1 (0.42) | NOTUMHDAC9ALDH1A1MEN1KMT2A | |
| SCHEMBL30645248 | 0.73 | NOTUM (0.45) | NOTUMHDAC9ALDH1A1MEN1KMT2A | |
| SCHEMBL8078233 | 0.73 | NOTUM (0.45) | NOTUMHDAC9ALDH1A1MEN1KMT2A | |
| SCHEMBL8114506 | 0.71 | NOTUM (0.43) | NOTUMHDAC9ALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186010-A | Synthesis method of atimetazole hydrochloride | 厦门欧瑞捷生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112225700-B | Preparation method of atemezole | 湖南新合新生物医药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-112225700-A | Preparation method of altimezole | 湖南新合新生物医药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
| EP-2225209-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009071584-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2009-06-11 | — | — | WO | disclosed |
| EP-0247764-B1 | 4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES, AND INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | ORION-YHTYMÀ OY (FI) | 1991-08-14 | — | — | EP | disclosed |
| US-5026868-A | Alpha-2 receptor antagonists | FARMOS-YHTYMA OY (FI) | 1991-06-25 | — | — | US | disclosed |
| US-4933359-A | 4(5)-substituted imidazole derivatives as α2 -adrenergic receptor blockers | FARMOS-YHTYMA OY (FI) | 1990-06-12 | — | — | US | disclosed |
| EP-0247764-A1 | 4(5)-Substituted imidazole derivatives, and intermediates and processes for their preparation | ORION-YHTYMÀ OY (FI) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | CYP3A5, CYP3A4, IPO5 | NOTUM 2023/4885HDAC9 3374/4885ALDH1A1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.